

Resource Summary Report

Generated by [NIF](#) on Sep 6, 2026

NCM460

RRID:CVCL_0460

Type: Cell Line

Proper Citation

CLS Cat# 305430, RRID:CVCL_0460

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0460

Proper Citation: CLS Cat# 305430, RRID:CVCL_0460

Description: Cell line NCM460 is a Spontaneously immortalized cell line with a species of origin Homo sapiens (Human)

Sex: Male

Defining Citation: [PMID:8842743](#), [PMID:26615870](#)

Comments: Donor information: Established from the normal tissue of a patient suffering from gastric cancer., Population: Hispanic.

Category: Spontaneously immortalized cell line

Organism: Homo sapiens (Human)

Name: NCM460

Synonyms: NCM-460

Cross References: BTO:BTO_0004306, EFO:EFO_0022704, MCCL:MCC:0000357, ChEMBL-Cells:ChEMBL4483158, ChEMBL-Targets:ChEMBL4483264, CLS:305430, Lonza:75, PubChem_Cell_line:CVCL_0460, Wikidata:Q54908241

ID: CVCL_0460

Vendor: CLS

Catalog Number: 305430

Record Creation Time: 20250423T101352+0000

Record Last Update: 20260905T185129+0000

Ratings and Alerts

No rating or validation information has been found for NCM460.

No alerts have been found for NCM460.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 820 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Fu D, et al. (2026) ETV4 Promotes Colorectal Cancer Progression by Reprogramming Asparagine Metabolism to Remodel the Stromal Microenvironment. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(26), e16557.

Feng M, et al. (2026) Carbohydrate responsive element binding protein promotes colorectal carcinogenesis via Wnt/ β -catenin pathway. *Oncogene*, 45(20), 1890.

Yang X, et al. (2026) Time-programmed Losmapimod release enhances ANXA1-associated efferocytosis for diabetic wound repair. *Journal of controlled release : official journal of the Controlled Release Society*, 396, 115051.

Sun T, et al. (2026) Early melatonin supplementation partially delays gastrointestinal aging. *Biochimica et biophysica acta. Molecular basis of disease*, 1872(8), 168344.

Wang G, et al. (2026) Hollow Cu₂O Nanozymes Enhance Probiotic Therapy for Colitis via Redox Homeostasis and TXNIP/NLRP3 Inflammasome Inhibition. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e76598.

Zheng D, et al. (2026) Oral administration of low-molecular-weight heparin ameliorates colitis by enhancing the gut mucus barrier via microbial tryptophan metabolites. *British journal of pharmacology*, 183(3), 560.

Feng Q, et al. (2026) CAMK1 Suppresses Anoikis Resistance and Liver Metastasis in Colorectal Cancer. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 40(10), e71946.

Zhang S, et al. (2026) Multi-Component Functionalized Bifidobacterium Longum Hydrogel for Multi-Target Integrated Therapy of Colitis-Associated Anxiety and Depression. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e76242.

Huo L, et al. (2026) EEPD1 Inhibition Unleashes Antitumor Immunity in Colorectal Cancer by Activating the cGAS-STING Pathway. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(34), e22826.

Ge R, et al. (2026) Anacardic Acid Inhibits Pde2a to Enhance Colonic Epithelial Barrier Integrity in the Improvement of Diabetic Cardiomyopathy. *Molecular nutrition & food research*, 70(8), e70464.

Huang Y, et al. (2026) Oral delivery of GLP-1 analogues by recombinant *Lactococcus lactis* restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice. *EBioMedicine*, 124, 106141.

Wang P, et al. (2026) Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. *Oncology research*, 34(2), 20.

Jin S, et al. (2026) IFITM1-targeted NIR-II fluorescence imaging enables visualisation of colorectal cancer and metastatic lymph nodes. *Journal of translational medicine*, 24(1).

Chen J, et al. (2026) Targeting NAT10 alleviates colonic senescence and elderly-onset colitis by disrupting N4-acetylation of DYRK1A. *Nature communications*, 17(1).

Li D, et al. (2026) ASCL2 drives colorectal cancer metastasis through transcriptional activation of TDGF1. *Cellular oncology (Dordrecht, Netherlands)*, 49(3).

Gong F, et al. (2026) Trans-presentation of IL-6R α by macrophages drives colorectal cancer development. *Cell reports*, 45(7), 117549.

Bradai N, et al. (2026) LC-ESI-MS/MS Characterization and Biological Activities of Ethyl Acetate and n-Butanol Fractions of *Chrysanthemum macrocarpum* From Algeria. *Chemistry & biodiversity*, 23(7), e71454.

Sun Q, et al. (2026) The subtype identification of colorectal cancer and construction of the risk model based on cholesterol synthesis-related genes to predict prognosis and guide immunotherapy. *International journal of colorectal disease*, 41(1), 24.

Yue Z, et al. (2026) Subcellular Redistribution of Endomembrane GPR15 Promotes NAD $^{+}$ -Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. *Cancer research*, 86(9), 2253.

Zhao Z, et al. (2026) Identification and Experimental Verification Reveal SLC2A3 Associated With Prognosis and Immune Infiltration in Colon Adenocarcinoma. *Mediators of inflammation*, 2026(1), e8383379.